According to recent data from Aon, 2-year utilization of GLP-1s can help employers lower medical costs by an average of 7%. Imagine benefits leaders and consultants could fast-forward a few years from now to see the evolution of these therapies and metabolic health. What advancements might we encounter in terms of anti-obesity medications, care delivery methods, and outcomes? What would medication spending and utilization look like?
Hop on the DeLorean with Dr. Rekha Kumar, MD, MS, Head of Medical Affairs, Laura Collymore, VP of Strategic Alliances, and Annie Whelan, Director of Partnerships, as they explore the future of obesity medicine in this webinar. Plus, learn about:
- GLP-1 trends, including prescribing and maintenance approaches
- The role of personalized care in prescribing anti-obesity medications
- Cost containment strategies that don't compromise access to care
